Atrial Septal Defect Market to be at Forefront by 2024

Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart’s two upper chambers, i.e., atria. The opening in the septum usually closes when the baby is born, but in few cases if the opening does not close, the hole is referred to as atrial septal defect. Huge and long-term atrial septal defects may lead to serious heart and lung damage. In some cases, extra blood volume can overfill the lungs and increases the blood pressure of the lungs, leading to pulmonary hypertension. Most of the congenital heart diseases are caused by certain genetic defects. The three most common types of atrial septal defects are ostium secundum atrial septal defect, ostium primum atrial septal defect and sinus venosus atrial septal.

Read Report Overview:

https://www.transparencymarketresearch.com/atrial-septal-defect-market.html

The medications which are used to reduce the signs and symptoms of atrial septal defect include beta blockers (Lopressor, Inderal), anticoagulants (Coumadin) and anti-platelet agents (aspirin). In some instances, surgery is also done to repair an atrial septal defect such as open-heart surgery and cardiac catheterization.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17066

Based on geography, the atrial septal defect market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Out of these regions, North America holds a leading position in the market followed by Europe. The prime factors which are driving the growth of atrial septal defect market in these regions are high prevalence of genetic heart disorders, and growing awareness of the population regarding atrial septal defects. Moreover, technological advancement in the treatment of congenital heart diseases is also accentuating the growth of the market. Asia Pacific is the most lucrative market for the growth of atrial septal defect market. The advantageous factors which would propel the growth of the market in Asia Pacific are presence of large population base and emerging economies such as China, Malaysia, India and Vietnam. Furthermore, favorable reimbursement policies and increasing disposable income of the Asian population would further boost the growth of atrial septal defect market in the coming years.

Various pharmaceutical companies are constantly trying to come up with novel therapeutic developments for the treatment of atrial septal defect. Some of the top major players operating in the atrial septal defect market are Asklepion Pharmaceuticals, LLC, Actelion Ltd., Novo Nordisk A/S, Abbott Laboratories, INO Therapeutics, LLC and others.

Request to View ToC of the report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=17066

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materia